


High-Throughput Mass Spectrometry in Drug Discovery

Edited By **Chang Liu** and **Hui Zhang**



WILEY

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Preface](#)

[List of Abbreviations](#)

[Section 1: Introduction](#)

[1 Forty-Year Evolution of High-Throughput Mass Spectrometry](#)

[1.1 Introduction](#)

[1.2 Ionization Foundations of High-Throughput Mass Spectrometry](#)

[1.3 High-Speed Serial Chromatographic Sample Introduction](#)

[1.4 Parallel Chromatographic Sample Introduction](#)

[1.5 High Repetition Rate Lasers](#)

[1.6 Ion Mobility for High-Speed Gas-Phase Separations](#)

[1.7 Mass Spectrometer Sensitivity](#)

[1.8 High-Speed Sub-Microliter Volume Sampling](#)

[1.9 Conclusions and Future Prospects](#)

[References](#)

[Section 2: LC-MS](#)

[2 The LeadSampler \(LS-1\) Sample Delivery System](#)

[2.1 Introduction](#)

[2.2 Hardware and System Design](#)

[2.3 Software Integration](#)

[2.4 Enabling Emerging Techniques](#)

[2.5 Concluding Remarks](#)

[References](#)

[3 Evolution of Multiplexing Technology for High-Throughput LC/MS Analyses](#)

[3.1 Introduction and Historical Developments](#)

[3.2 Developments Toward Fully Integrated Multiplexing Systems](#)

[3.3 Broadening Customer Options](#)

[3.4 Workflow and End-User Considerations](#)

[3.5 Conclusion](#)

[References](#)

[Section 3: ESI-MS Without Chromatographic Separation](#)

[4 Direct Online SPE-MS for High-Throughput Analysis in Drug Discovery](#)

[4.1 Introduction](#)

[4.2 History of the Development of Direct Online SPE-MS](#)

[4.3 Hardware Details and Data Processing](#)

[4.4 Instrument Performance Highlights](#)

[4.5 Applications](#)

[4.6 Others](#)

[4.7 Future Perspectives](#)

[References](#)

[5 Acoustic Sampling for Mass Spectrometry](#)

[5.1 Introduction](#)

[5.2 Technology Overview](#)

[5.3 System Performance](#)

[5.4 Applications](#)

[5.5 Challenges and Limitations](#)

[5.6 Conclusion](#)

[References](#)

[6 Ion Mobility Spectrometry-Mass Spectrometry for High-Throughput Analysis](#)

[6.1 Introduction of Ion Mobility Spectrometry](#)

[6.2 IMS Fundamental and Experiment](#)

[6.3 IMS Analysis and Applications](#)

[6.4 High-Resolution SLIM-IMS Developments](#)

[6.5 Conclusions](#)

[References](#)

[7 Differential Mobility Spectrometry and Its Application to High-Throughput Analysis](#)

[7.1 Introduction](#)

[7.2 Separation Speed](#)

[7.3 Separation Selectivity](#)

[7.4 Ultrahigh-Throughput System with DMS](#)

[7.5 Conclusions](#)

[7.A Chemical Structures](#)

[References](#)

[Section 4: Special Sample Arrangement](#)

[8 Off-Line Affinity Selection Mass Spectrometry and Its Application in Lead Discovery](#)

[8.1 Introduction to Off-Line Affinity Selection Mass Spectrometry](#)

[8.2 Selected Off-Line Affinity Selection Technologies and Its Application in Lead Discovery](#)

[8.3 Future Perspectives](#)

[References](#)

[9 Online Affinity Selection Mass Spectrometry](#)

[9.1 Introduction of Online Affinity Selection-Mass Spectrometry](#)

[9.2 Online ASMS Fundamental](#)

[9.3 Instrument Hardware and Software Consideration](#)

[9.4 Type of Assays Using ASMS](#)

[9.5 Applications Examples and New Modalities of ASMS for Drug Discovery](#)

[9.6 Future Perspectives](#)

[References](#)

[10 Native Mass Spectrometry in Drug Discovery and Development](#)

[10.1 Introduction](#)

[10.2 Fundamentals of Native MS](#)

[10.3 Instrumentation](#)

[10.4 Application Highlights](#)

[10.5 Conclusions and Future Directions](#)

[References](#)

[Section 5: Other Ambient Ionization Other than ESI](#)

[11 Laser Diode Thermal Desorption-Mass Spectrometry \(LDTD-MS\)](#)

[11.1 A Historical Perspective of the LDTD](#)

[11.2 Instrumentation](#)

[11.3 Theoretical Background](#)

[11.4 Sample Preparation](#)

[11.5 Applications](#)

[11.6 Conclusion](#)

[References](#)

[12 Accelerating Drug Discovery with Ultrahigh-Throughput MALDI-TOF MS](#)

[12.1 Introduction](#)

[12.2 uHT-MALDI MS of Assays and Chemical Reactions](#)

[12.3 Bead-Based Workflows](#)

[12.4 Using Functionalized, Modified, and Microarrayed MALDI Plates for HT-MALDI](#)

[12.5 Summary and Future Trends](#)

[Acknowledgment](#)

[References](#)

[13 Development and Applications of DESI-MS in Drug Discovery](#)

[13.1 Introduction](#)

[13.2 Development of DESI and Related Ambient Ionization Methods](#)

[13.3 Applications in Drug Discovery](#)

[13.4 Conclusions and Future Outlook](#)

[References](#)

[Section 6: Conclusion](#)

[14 The Impact of HT-MS to Date and Its Potential to Shape the Future of Metrics-Based Experimentation and Analysis](#)

[14.1 Defining High-Throughput Mass Spectrometry \(HT-MS\)](#)

[14.2 HT-MS: Impact to Date](#)

[14.3 Considering How HT-MS Will Shape the Future of Drug Discovery](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 2

[Table 2.1 Volumes associated with system components and plumbing.](#)

[Table 2.2 Volumes of flow path components identified in Panel B.](#)

[Table 2.3 Resource savings and operational efficiency resulting from reconf...](#)

[Table 2.4 Summary of in vitro pharmacokinetic screens, associated methodolo...](#)

Chapter 7

[Table 7.1 Ratio of signal intensity for standards of mirtazapine to the sam...](#)

[Table 7.2 Comparison of peak areas for a panel of compounds with a DMS cell...](#)

Chapter 12

[Table 12.1 Examples of enzymatic assays, chemical reactions, and cell-based...](#)

List of Illustrations

Chapter 1

[Figure 1.1 Histomap of LC/MS interfaces from 1967 to present and some emergi...](#)

[Figure 1.2 The evolution of electrospray LC/MS interfaces. \(a\) The ion evapo...](#)

[Figure 1.3 First demonstration of the feasibility of HT-MS using the heated ...](#)

[Figure 1.4 Images and applications of the first ambient sampling_\(aka ambien...](#)

[Figure 1.5 Images and applications of the second ambient sampling_\(aka ambie...](#)

[Figure 1.6 High flow rate ESI ion source operating at 800 °C. Evaporative co...](#)

[Figure 1.7 Fast serial, staggered chromatography systems and autosamplers to...](#)

[Figure 1.8 MRM ion current trace using a monolithic stationary phase casted ...](#)

[Figure 1.9 Illustration of the four positions where signal can be toggled on...](#)

[Figure 1.10 Two examples of indexing systems prototyped and tested. \(a\) Flui...](#)

[Figure 1.11 Ion production indexing. \(a\) Photograph of the Medusa ion source...](#)

[Figure 1.12 Components of the multichannel autosampler \(Parker-Hannifin\) and...](#)

[Figure 1.13 The prototype MALDI ion source adapted to a triple quadrupole in...](#)

[Figure 1.14 Example of the improvement in quantitative data when using a hig...](#)

[Figure 1.15 Illustrations of a differential ion mobility analyzer coupled to...](#)

[Figure 1.16 Ionograms created by scanning the CV voltage during a continuous...](#)

[Figure 1.17 Graph of the incremental gains in the sensitivity of commercial ...](#)

[Figure 1.18 Data from three compounds of varying ionization efficiency using...](#)

[Figure 1.19 \(a\) Diagram of a prototype Acoustic Ejection Mass Spectrometry s...](#)

[Figure 1.20 \(a\) Axial cross-section of the OPI interface operating under con...](#)

[Figure 1.21 \(a\) Sonogram of 1536 samples dispensed as one 5 nL drop per samp...](#)

[Figure 1.22 \(a\) Data illustrating limits of quantitation and suppression eff...](#)

[Figure 1.23 Different modes of operating AEMS. \(a\) Data illustrating the abi...](#)

[Figure 1.24 \(a\) Chronograms illustrating the multiplexing method to increase...](#)

[Figure 1.25 Chronogram using an OPI interface modified to obtain maximum spe...](#)

Chapter 2

[Figure 2.1 Drug discovery LC-MS-based screening pathways. Although project t...](#)

[Figure 2.2 Prototype LeadSampler platform. \(a\) System overview. 1. Cavro[®]...](#)

[Figure 2.3 The current LeadSampler platform. The Sciex 6500 mass spectromete...](#)

[Figure 2.4 \(a\) LC trace with "standard" configuration: HALO C18 direct-conne...](#)

[Figure 2.5 Bioanalytical data from high-throughput in vitro pharmacokinetic ...](#)

[Figure 2.6 Flow of information through key touchpoints in the LeadScape bioa...](#)

[Figure 2.7 LeadScape Top-level interface. Working from left to right the use...](#)

[Figure 2.8 The user can import a text file list of compounds and query the d...](#)

[Figure 2.9 Import text file with positions. Users can customize import and e...](#)

[Figure 2.10 LeadScape user interfaces for configuring input and data formatt...](#)

[Figure 2.11 LeadScape queue displays status of past, current, and future sub...](#)

[Figure 2.12 Comparison of sample-consolidation strategies for enhancing oper...](#)

[Figure 2.13 LeadSampler system optimized specifically for micro-flow LC-MS/M...](#)

[Figure 2.14 Impact of post-column system volume on microflow LC-MS/MS chroma...](#)

Chapter 3

[Figure 3.1 Schematic representation of the general multiplexing process for ...](#)

Chapter 4

[Figure 4.1 Direct online SPE with a dual-cartridge configuration, as first r...](#)

[Figure 4.2 RapidFire instrument \(RapidFire 365\) picture.](#)

[Figure 4.3 Valve positions and flow paths during RapidFire operation: \(a\) as...](#)

[Figure 4.4 Typical RapidFire-MS data from a transporter inhibition assay, wi...](#)

Chapter 5

[Figure 5.1 \(a\) A - Source block of Waters SQDII, B - capillary transfer line...](#)

[Figure 5.2 \(a\) A - Echo 555 transducer, B - heated transfer capillary, C - c...](#)

[Figure 5.3 \(a\) Schematic of early AMI-MS charging system. The resistive glas...](#)

[Figure 5.4 \(a\) Acoustic mist ionization \(AMI\) hardware used for high-through...](#)

[Figure 5.5 CE-compliant version of AMI-MS system.](#)

[Figure 5.6 Diagram of an ADE-OPI-MS system. \(A\) Acoustic transducer. \(B\) Dro...](#)

[Figure 5.7 Well-to-well variability assessment for a 384-well plate containi...](#)

[Figure 5.8 \(a\) Linearity of signal from example biomolecular analytes of int...](#)

[Figure 5.9 \(a\) TIC generated by AMI-MS from 384-well plates. Each packet of ...](#)

[Figure 5.10 Peptide and protein spectra from AMI-MS. \(a\) Multiple-charged sp...](#)

[Figure 5.11 HDAC inhibition screen. \(a\) Overview of the HDAC assay. \(b\) Exam...](#)

[Figure 5.12 HTS output for HDAC screening campaign. \(a\) Robust Z' fact...](#)

[Figure 5.13 A representation of the original data analysis workflow for AMI-...](#)

[Figure 5.14 The application of the ADE-OPI-MS system for the DGAT2 screening...](#)

[Figure 5.15 Examples of data generated to support assay development using AM...](#)

[Figure 5.16 The application of the ADE-OPI-MS system for in situ kinetics st...](#)

[Figure 5.17 Use of metal ion chelator to identify zinc contamination in comp...](#)

[Figure 5.18 AMI-MS spectra from cell lysates. \(a\) Spectrum from MCF7 cell ly...](#)

Chapter 6

[Figure 6.1 Schematics of a typical IMS-MS instrument and conformation separa...](#)

[Figure 6.2 Example of an arrival time, \$t_A\$, versus \$P/V\$ plot to determine the ...](#)

[Figure 6.3 Examples of IMS separation of isomeric species separation \(a\) and...](#)

[Figure 6.4 \$^{DT}CCS_{N2}\$ database for small molecules: \(a\) CCS values of small mol...](#)

[Figure 6.5 IM-MS conformational space plots showing the regions occupied by ...](#)

[Figure 6.6 Coupling solid-phase extraction, ion mobility spectrometry, and m...](#)

[Figure 6.7 \(a\) A schematic and photograph of the serpentine 13-m SLIM IMS-MS...](#)

[Figure 6.8 2D IMS-MS plot of the reduced antibody-drug conjugate after a 4.5...](#)

Chapter 7

[Figure 7.1 Orthogonality of DMS separations versus \$m/z\$ for three different c...](#)

[Figure 7.2 Q1 scans for chlordiazepoxide and temazepam.](#)

[Figure 7.3 \(a\) LC separation of 1. chlordiazepoxide and 2. temazepam. \(b\) MR...](#)

[Figure 7.4 Separation of the structural isomers: 1. morphine, 2. hydromorpho...](#)

[Figure 7.5 Separation of the structural isomers: 1. oxymorphone, 2. dihydroc...](#)

[Figure 7.6 Mirtazapine FIA signal taken with 5 \$\mu\$ L injection for \(a\) standard...](#)

[Figure 7.7 Zoom of AEMS/DMS/MS data for Mirtazapine samples prepared in urin...](#)

[Figure 7.8 Analytical signal with increased injection volumes using an AEMS ...](#)

[Figure 7.9 Suppression effects for samples prepared in urine versus desaltin...](#)

[Figure 7.10 Schematic of an AEMS system with DMS system.](#)

[Figure 7.11 Coefficient of variation \(CV\) versus points across a peak for pe...](#)

[Figure 7.12 Raw data for four replicate AEMS injections using instrument con...](#)

[Figure 7.13 Switching between pseudo-continuous signal mode and pulsed mode....](#)

[Figure 7.14 Comparison of separations for clozapine and midazolam using tee ...](#)

[Figure 7.15 Replicate measurements for reserpine injections with a DMS insta...](#)

[Figure 7.16 Zoomed view of the plot of reserpine signal intensity with a DMS...](#)

[Figure 7.17 Replicate measurements for minoxidil injections with a DMS insta...](#)

[Figure 7.18 Zoomed view of the plot of minoxidil signal intensity with a DMS...](#)

[Figure 7.19 AEMS data for injection of a mirtazapine standard while measurin...](#)

[Figure 7.20 AEMS data for injection of a desmethyldoxepin standard while mea...](#)

[Figure 7.21 Overlay of DMS ionograms for desmethyldoxepin \(gray trace\) and m...](#)

[Figure 7.22 AEMS data for mirtazapine and desmethyldoxepin with a DMS instal...](#)

[Figure 7.23 Calibration curves for mirtazapine in desalted urine. The inject...](#)

[Figure 7.24 Calibration curves for desmethyldoxepin in desalted urine. The i...](#)

[Figure 7.25 Overlay of Q1 spectra for midazolam \(gray trace\) and clozapine \(...\)](#)

[Figure 7.26 Midazolam and clozapine example showing midazolam injection \(a\)...](#)

[Figure 7.27 Separation of acetaminophen and phenacetin using \(a\) LC/MS and \(...\)](#)

[Figure 7.28 LC/MS data for injection of a phenacetin sample: \(a\) MRM signal ...](#)

[Figure 7.29 Raw data for injections of fentanyl samples prepared in desalted...](#)

[Figure 7.30 Calibration curves for fentanyl from a desalted urine sample acq...](#)

[Figure 7.31 Blank injections for norfentanyl from a desalted urine sample wi...](#)

[Figure 7.32 Overlay of a series of ionograms for determining the alpha curve ...](#)

[Figure 7.33 Alpha curves for amobarbital and pentobarbital.](#)

[Figure 7.34 Difference function for the alpha curves for amobarbital and pen...](#)

[Figure 7.35 DMS separation for a mixture containing pentobarbital and amobar...](#)

[Figure 7.36 Alpha curves for a group of five isobaric and near-isobaric benz...](#)

[Figure 7.37 Alpha example of the separation with the separation field set to...](#)

Chapter 8

[Figure 8.1 Schematic diagram of on-line versus off-line affinity selection m...](#)

[Figure 8.2 Membrane ultrafiltration-based affinity selection mass spectromet...](#)

[Figure 8.3 Pulsed ultrafiltration-mass spectrometry \(PUF-MS\) for screening o...](#)

[Figure 8.4 "SpeedScreen sandwich" assembly of three microtiter plates \(in ei...](#)

[Figure 8.5 Relative binding affinity percentage %-RBA \(y-axis\) of 100 small ...](#)

[Figure 8.6 JQ1 and bromosporine profiling of the bromodomain panel. \(a\) Inte...](#)

[Figure 8.7 Schematic for the MagMASS approach for off-line affinity selectio...](#)

[Figure 8.8 Schematic for ASMS workflow using self-assembled monolayers and m...](#)

[Figure 8.9 Correlation of SAMDI ASMS data with an orthogonal biochemical bin...](#)

[Figure 8.10 Schematic of ultracentrifugation-based strategy for multiplexed ...](#)

[Figure 8.11 Concentration distributions for proteins and tool compounds foll...](#)

Chapter 9

[Figure 9.1 Typical setup of the online ASMS with 2-D LC/MS configurations....](#)

[Figure 9.2 The time-dependent dissociation profiles simulated for a potent l...](#)

[Figure 9.3 Potential ASMS applications throughout the drug discovery and dev...](#)

[Figure 9.4 One successful example of identifying clinical drug candidates wi...](#)

Chapter 10

[Figure 10.1 Illustration of the electrospray ionization process of protein a...](#)

[Figure 10.2 Illustration of the inline-desalting process. Non-volatile salt ...](#)

[Figure 10.3 SEC-IEX-nMS chromatogram and spectra of reslizumab and bevacizum...](#)

[Figure 10.4 Representation of the nLC-MS platform.](#)

[Figure 10.5 Depiction of the two modes of operation for the fluidic channel ...](#)

Chapter 11

[Figure 11.1 LDTD process. The laser path is shown heating the back of the sa...](#)

[Figure 11.2 The sample holder with standard dimensions \(ANSI footprint\) for ...](#)

[Figure 11.3 Schematic view of \(a\) the sample preparation deposited on the we...](#)

[Figure 11.4 The schematic view shows the two concentric tubes of the extract...](#)

[Figure 11.5 Logarithmic relationship between the desorption rate and the hea...](#)

[Figure 11.6 Normalized intensity of sulfadiazine compared to the temperature...](#)

[Figure 11.7 Maxwell-Boltzmann distribution.](#)

[Figure 11.8 Dried deposit of prednisone on a surface well magnified \(a\) 30 X...](#)

[Figure 11.9 Carrier gas flow and temperature profile. The carrier gas enters...](#)

[Figure 11.10 Relative abundance versus number of water cluster for different...](#)

[Figure 11.11 Relative signal intensity versus the rate of molecules desorbed...](#)

[Figure 11.12 Schematic of the signal intensity versus the volume deposited o...](#)

[Figure 11.13 Peak shape characterization when ionic saturation occurs, with ...](#)

[Figure 11.14 Typical laser pattern shape. The length of the power ramp and t...](#)

[Figure 11.15 LogD plot for three compounds with distinct behavior.](#)

[Figure 11.16 Correlation plot between the IC₅₀ values obtained form LDTD-APC...](#)

[Figure 11.17 Area counts for different volumes deposited in the well for the...](#)

[Figure 11.18 \(a\) 384 samples of the same concentration of OH-Midazolam acqui...](#)

[Figure 11.19 Calibration curve of dextrorphan acquired with a throughput of ...](#)

[Figure 11.20 Comparison of IC₅₀ curves obtained by LDTD and RapidFire, showi...](#)

[Figure 11.21 Caco-2 model.](#)

[Figure 11.22 Cross validation of permeability analysis of Caco-2/TCY between...](#)

[Figure 11.23 LDTD-AMS SWATH method data for a full 384 well plate. \(a\) shows...](#)

[Figure 11.24 Dilution ratio optimization for a protein precipitate in plasma...](#)

[Figure 11.25 Results for the Quetiapine with a 250 nL volume deposited on th...](#)

[Figure 11.26 \(a\) Mean plasma concentration-time profiles of 27 subjects admi...](#)

Chapter 12

[Figure 12.1 Results from the cGAS HTS assay campaign and hit triaging. \(a\) Z](#)

[Figure 12.2 Workflow for uHT-MALDI screening of chemical reactions. The first...](#)

[Figure 12.3 uHT-MALDI MS approach to screening potential reaction poisons. \(...\)](#)

[Figure 12.4 Automated workflow of the cellular MALDI MS uptake assay: Adhere...](#)

[Figure 12.5 Scheme of MALDI-TOF affinity selection mass spectrometry \(AS-MS\)...](#)

[Figure 12.6 Bead-assisted mass spectrometry \(BAMS\) workflow. Lysed and diges...](#)

Chapter 13

[Figure 13.1 Schematics of \(a\) desorption electrospray ionization \(DESI\), \(b\)...](#)

[Figure 13.2 \(a\) Schematic of a typical TLC-DESI-MS system for natural produc...](#)

[Figure 13.3 \(a\) Scanned optical image of a sagittal whole-body tissue sectio...](#)

[Figure 13.4 \(a\) Schematic of liquid sample DESI-MS for analysis protein-liga...](#)

[Figure 13.5 Workflow of a high-throughput reaction screening system with DES...](#)

High-Throughput Mass Spectrometry in Drug Discovery

Edited by

Chang Liu

SCIEX

Concord, Canada

Hui Zhang

Entos Inc.

La Jolla

USA

WILEY

This edition first published 2023
© 2023 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Chang Liu and Hui Zhang to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further,

readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data applied for
Hardback ISBN: 9781119678434

Cover Design: Wiley

Cover Images: Back cover image courtesy of Thomas R. Covey and Ella Potyrala

Cover Image: Courtesy of Thomas R. Covey

Cover Design Concept: Courtesy of Ella Potyrala

List of Contributors

Leigh Bedford

SCIEX, Concord, ON, Canada

Aivett Bilbao

Earth and Biological Sciences Directorate, Pacific
Northwest

National Laboratory

Richland, WA, USA

Thomas R. Covey

SCIEX, Concord, ON, Canada

Sammy Datwani

Beckman Coulter Life Sciences

San Jose, CA, USA

Sergei Dikler

Bruker Scientific, LLC

Billerica, MA, USA

Eva Duchoslav

SCIEX, Concord, ON, Canada

Lucien Ghislain

Beckman Coulter Life Sciences

San Jose, CA, USA

John Janiszewski

National Center for Advancing Translational Sciences
(NCATS)

Rockville, MD, USA

Mengxuan Jia

Preclinical Development ADMET/BAMerck & Co., Inc

South San Francisco, CA, USA

Yang Kang

SCIEEX, Concord, ON, Canada

Brendon Kapinos

Pfizer Worldwide Research and Development, Groton, CT,
USA

Adam Latawiec

SCIEEX, Concord, ON, Canada

Sylvain Letarte

R&D Department, Phytronix Technologies Inc., Québec
QC, Canada

Chang Liu

SCIEEX, Concord, ON, Canada

Juncai Meng

Discovery Technology and Molecular Pharmacology (DTMP)
Janssen Research & Development
LLC, Spring House, PA, USA

Olivier Mozziconacci

Discovery Pharmaceutical Sciences
Merck & Co., Inc, South San Francisco
CA, USA

Réal E. Paquin

Université Laval
Québec, QC, Canada

Pierre Picard

R&D Department, Phytronix Technologies Inc., Québec
QC, Canada

Elizabeth Pierson

Analytical R&D, Merck & Co., Inc.,
Rahway, NJ, USA

Subhasish Purkayastha

SCIEEX, Framingham, MA, USA

Jonathan Rochon

R&D Department, Phytronix Technologies Inc.,
Québec, QC, Canada

Dylan H. Ross

Earth and Biological Sciences Directorate, Pacific
Northwest National Laboratory
Richland, WA, USA

Bradley B. Schneider

SCIEX, Concord, ON, Canada

Wilson Z. Shou

Lead Discovery and Optimization
Bristol-Myers Squibb Company
Princeton, NJ, USA

Richard D. Smith

Earth and Biological Sciences Directorate, Pacific
Northwest National Laboratory
Richland, WA, USA

Aaron Stella

SCIEX, Framingham, MA, USA

Christopher F. Stratton

Discovery Technology and Molecular Pharmacology
(DTMP), Janssen Research & Development, LLC
Spring House, PA, USA

Lawrence M. Szewczuk

Discovery Technology and Molecular Pharmacology
(DTMP), Janssen Research & Development, LLC
Spring House, PA, USA

Matthew D. Troutman

Hit Discovery and Optimization
Pfizer, Inc., Groton, CT, USA

Andrew D. Wagner

Lead Discovery and Optimization

Bristol-Myers Squibb Company
Princeton, NJ, USA

Jianzhong Wen

Preclinical Development ADMET/BAMerck & Co., Inc
South San Francisco, CA, USA

Jonathan Wingfield

Mechanistic and Structural Biophysics
Discovery Sciences, R&D
AstraZeneca, Cambridge, UK

Hui Zhang

Entos Inc.
Department of Analytical Technologies, Entos
San Diego, CA, USA

Wenpeng Zhang

State Key Laboratory of Precision Measurement
Technology and Instruments, Department of Precision
Instrument, Tsinghua University
Beijing, China

Xueyun Zheng

Earth and Biological Sciences Directorate, Pacific
Northwest National Laboratory, Richland, WA, USA

time-of-flight (TOF) mass analyzers

- acoustic sampling [148](#), [155](#)-156, [171](#)-172
- direct online SPE-MS [134](#)
- historical development [32](#), [35](#)
- ion mobility spectrometry [187](#)
- laser diode thermal desorption [378](#)
- native mass spectrometry [329](#)
- online affinity selection mass spectrometry [297](#), [302](#)-303
- ultrahigh-throughput MALDI-TOF MS [393](#)-421

time-resolved fluorescence energy transfer (TR-FRET) [286](#)

TIMS *see* [trapped ion mobility spectrometry](#)

TLC *see* [thin layer chromatography](#)

TMA-lyase *see* [trimethylamine-lyase](#)

TM-DESI *see* [transmission mode desorption electrospray ionization](#)

TM-IMS *see* [transversal modulation ion mobility spectrometry](#)

TOF *see* [time-of-flight](#)

total ion current (TIC) [156](#), [159](#)

TPD *see* [targeted protein degradation](#)

transmission mode desorption electrospray ionization (TM-DESI) [436](#), [436](#)

transversal modulation ion mobility spectrometry (TM-IMS) [184](#)

trap and elute method [125](#)

trapped ion mobility spectrometry (TIMS)
 concepts and definitions [184](#)
 historical development [36](#)
 ultrahigh-throughput MALDI-TOF MS [414](#)

trastuzumab emtansine [333](#)

traveling wave ion mobility spectrometry (TWIMS)
 high-throughput analysis [184](#), [193](#)-195, [194](#), [200](#)
 historical development [36](#)

TR-FRET *see* [time-resolved fluorescence energy transfer](#)

trimethylamine-lyase (TMA-lyase) [405](#)-406

triple quadrupole mass spectrometer [217](#), [220](#)-223, [233](#),
[238](#)-239

tumor cell percentage (TCP) [433](#)-434

TurboFlow chromatography [105](#)-107

TWIMS *see* [traveling wave ion mobility spectrometry](#)

tyrosine phosphatase 1B [289](#), [290](#), [399](#)-401, [412](#)-413

u

ubiquitylation cascade pathway [401](#)

UFA *see* [unbound fraction analysis](#)

UHPLC *see* [ultrahigh performance liquid chromatography](#)

uHT *see* [ultrahigh-throughput](#)

ultracentrifugation
 advantages and disadvantages [320](#)
 affinity selection [286](#)-291, [288](#), [290](#)

ultrahigh performance liquid chromatography (UHPLC)
 LeadSampler sample delivery system [78-81](#)
 multiplexing technology [103-104](#), [112](#)

ultrahigh-throughput (uHT) MALDI-TOF MS [393-421](#)
 bead-based workflows [408-410](#), [410](#)
 cell-based assays [397-398](#), [404-406](#), [405](#), [412-413](#)
 enzymatic assays [396-401](#), [397-398](#), [400](#), [410](#), [412](#)
 functionalized, modified, and microarrayed MALDI
 plates [411-413](#)
 future directions [413-414](#)
 historical development [393-396](#)
 other assay and library types [406-408](#), [407](#)
 screening chemical reactions [397-398](#), [401-402](#), [402-403](#)

ultra performance liquid chromatography (UPLC) [24](#),
[373-378](#), [377](#)

ultraviolet photodissociation (UVPD) [334](#)

ultraviolet (UV) detection [105](#)

unbiased binding assay [298](#)

unbound fraction analysis (UFA) [272](#), [272](#)

UPLC *see* [ultra performance liquid chromatography](#).

UV *see* [ultraviolet](#)

UVPD *see* [ultraviolet photodissociation](#)

V

vaccines [336-337](#)

virus proteins [336](#)-337

volume sampling

historical development [42](#)-53, [45](#), [47](#)-49, [51](#)-54

shoot 'n' dilute nanoliter droplets [44](#)-53, [45](#), [47](#)-49, [51](#)-54

small sample size/low volume HT-MS technologies [42](#)-44

W

warfarin [309](#)

WBA *see* [whole-body autoradiography](#)

well-to-well variability [155](#), [156](#)

whole-body autoradiography (WBA) [432](#)-433, [433](#)

X

xenobiotics [190](#)-193, [191](#)

X-ray crystallography (XRC) [335](#)-336

X-ray diffraction (XRD) [319](#)

Z

Zirconium Ultra pump [93](#)